Inhibition of phosphate transport in human erythrocytes by water-soluble carbodiimides.
Phosphate entry into human erythrocytes is irreversibly inhibited by treatment of the cells with the water-soluble carbodiimides 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 1-cyclohexyl-3-(2-morpholinoethyl)-carbodiimide metho-p-toluene sulfonate (CMC) in the absence of added nucleophile. EDC is the more potent inhibitor (40% inhibition, 2 mM EDC, 5 min, 37 degrees C, 50% hematocrit, pH 6.9), while more than 20 mM CMC is required to give the same inhibition under identical conditions. EDC inhibition is temperature-dependent, being complete in 5 min at 37 degrees C, and sensitive to extracellular pH. At pH 6.9 only 50% of transport is rapidly inhibited by EDC, but at alkaline pH over 80% of transport is inhibited. Inhibition is not prevented by modification of membrane sulfhydryl groups but is decreased in the presence of 4,4'-dinitrostilbene-2,2'-disulfonic acid (DNDS), a reversible competitive inhibitor of anion transport. EDC treatment leads to crosslinking of erythrocyte membrane proteins, but differences between the time course of this action and inhibition of transport indicate that most transport inhibition is not due to crosslinking of membrane proteins.
D001665:Binding Sites; D003028:CME-Carbodiimide / Q000031:analogs & derivatives / Q000494:pharmacology*; D002234:Carbodiimides / Q000494:pharmacology*; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism*; D005022:Ethyldimethylaminopropyl Carbodiimide / Q000494:pharmacology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D008565:Membrane Proteins / Q000032:analysis; D010710:Phosphates / Q000097:blood*; D013267:Stilbenes / Q000494:pharmacology; D013997:Time Factors
D002234:Carbodiimides; D008565:Membrane Proteins; D010710:Phosphates; D013267:Stilbenes; D003028:CME-Carbodiimide; C022306:4,4'-dinitro-2,2'-stilbenedisulfonic acid; D005022:Ethyldimethylaminopropyl Carbodiimide